How LLMs Are Transforming Pharma Manufacturing Operations

Pharmaceutical manufacturing is one of the most documentation-intensive industries in existence. GMP compliance requires that virtually every action, decision, and observation be recorded, reviewed, and retained. Batch records, deviation reports, change controls, SOPs, validation protocols, CAPA records — the paper trail that surrounds a drug product is, in many facilities, as labor-intensive as the manufacturing itself.

For years, that documentation burden has been something pharma teams simply absorbed. LLMs are beginning to change the calculus — not by reducing the rigor of documentation, but by making the generation, review, and analysis of that documentation dramatically more efficient.

Where LLMs Are Having Impact

Batch Record Review

Batch record review is a mandatory step before any drug product can be released. Quality assurance reviewers read through manufacturing records — sometimes hundreds of pages for a complex biologic — checking for completeness, consistency, and any anomalies that require investigation.

This is exactly the kind of work LLMs can assist with: reading structured and semi-structured text, identifying missing entries, flagging entries that fall outside expected ranges or that don’t align with the batch record template, and generating an initial exception report for QA review.

The human reviewer’s time shifts from reading everything to verifying the AI’s flags and making release decisions. The work is faster, more consistent, and less dependent on the individual reviewer’s fatigue level on a given day.

Deviation Investigation and CAPA

Deviation investigations require a quality professional to review what happened, identify root cause, and document a corrective and preventive action plan. The investigation itself often involves reading related batch records, previous deviations, SOPs, and equipment logs — a significant research burden.

LLMs can accelerate this research by retrieving and summarizing relevant historical documents: similar deviations, associated products, implicated equipment or personnel, prior CAPAs for related issues. This gives the investigator a head start and reduces the risk of missing relevant context that’s buried in the document management system.

On the drafting side, LLMs can generate initial CAPA narratives based on the investigator’s inputs, following regulatory writing conventions and the company’s standard format. The investigator reviews and finalizes; the time spent on initial drafting drops.

SOP Review and Q&A

Standard operating procedures are the backbone of GMP operations, but they’re often difficult to navigate. Finding the right SOP for a specific task, understanding how procedures interact, answering questions about edge cases — these are daily challenges for manufacturing staff and QA teams alike.

A RAG system grounded in a facility’s current SOP library can answer natural-language questions accurately: “What is the cleaning verification requirement for this equipment after a product changeover?” or “What are the steps for releasing a batch that had an IPC failure corrected under this procedure?”

This improves compliance by making the right information easier to find, reduces reliance on informal knowledge passed between colleagues, and can flag when a question touches an area where the SOP library may be incomplete or contradictory.

Change Control Documentation

Change control is one of the most document-intensive processes in pharma operations. Initiating a change requires assessing impact across product quality, regulatory filings, validations, supplier qualifications, and related SOPs — and documenting that assessment thoroughly.

LLMs can assist by reviewing the proposed change and cross-referencing it against the existing document corpus: identifying related products, affected procedures, open validations, and prior regulatory commitments that the change may implicate. This impact assessment work is currently done manually and can take significant time.

Draft change control narratives — the written description of what is changing, why, and what the quality impact assessment shows — can also be generated as first drafts for quality team review.

Regulatory Submission Support

Regulatory writing for INDs, NDAs, MAAs, and their supplements is specialized, high-stakes work. LLMs trained or prompted with regulatory writing conventions can assist with drafting narrative sections: module descriptions, risk assessments, justifications for proposed specifications.

This doesn’t reduce the need for experienced regulatory affairs professionals who understand how agencies will read submissions. It reduces the time they spend on initial drafting and document assembly, giving them more capacity for strategy and review.

The Compliance Architecture That Makes This Work

Pharma is an FDA and EMA-regulated industry. AI systems used in GMP-adjacent processes require a level of governance rigor that most other industries don’t.

Validation. Any software system used in GMP operations must be validated. This means documented qualification of the AI system’s intended use, testing against representative inputs, and a validation report. “We tried it and it seemed to work” is not sufficient.

Audit trails. 21 CFR Part 11 and equivalent EU requirements mandate that electronic records include audit trails capturing who did what and when. AI outputs, human reviews of those outputs, and any edits need to be captured in compliant audit trails.

Human oversight for quality decisions. AI can accelerate the work of batch record review or CAPA drafting. It cannot make the release decision. GMP regulations require that qualified humans take responsibility for quality decisions. The AI is a tool to assist that human judgment, not to replace it.

Data sovereignty. Batch records, deviation reports, and regulatory filings contain highly sensitive manufacturing information. Cloud-based AI services that may use submitted data for model training are not appropriate for this content. Private deployment on company infrastructure is the standard approach.

Change control for the AI system itself. When you update the AI system — new model version, changed prompts, different retrieval configuration — that update should go through change control, just like any other change to a GMP-supporting system.

The Opportunity in the Backlog

One underappreciated opportunity in pharma AI is historical document analysis. Most facilities have years or decades of deviation reports, CAPAs, batch records, and investigation files — stored in document management systems and largely unanalyzed at scale.

LLMs make it possible to run analytical queries across this historical corpus: “What are the most common root cause categories for deviations on this product line over the last five years?” or “Which pieces of equipment appear most frequently in investigations?” This kind of analysis could previously only be done by manually reading hundreds of documents or by labor-intensive data entry into structured databases.

That institutional knowledge — locked in unstructured text — is now accessible in a way it wasn’t before. That’s a significant operational advantage for teams thinking about continuous improvement and risk management.

Getting Started

The pharma teams moving most effectively on AI are starting with well-defined, high-document-volume processes — batch record review, SOP Q&A, deviation trending — rather than trying to automate the most complex regulatory tasks first.

They’re building on private infrastructure, establishing appropriate validation frameworks, and maintaining clear human review workflows. And they’re treating the AI system as a quality tool that needs to meet the same standards as the rest of their quality infrastructure.

Komposer’s platform is designed to support exactly this kind of deployment: private, observable, with full audit trails and integration into the document management and quality systems pharma teams already rely on. The goal isn’t to replace the quality function — it’s to give quality professionals the leverage they need to maintain rigor at scale.